PBAC
‘A’ flagging has Medicines Australia concerned
Medicines Australia has expressed concern about the PBAC’s recommendation that pharmacists be allowed to substitute the biosimilars in place of biologic medicines prescribed by a patient’s doctor. “The so-called ‘a-flagging’ …
Government must act on new hepatitis C meds, says peak body
The Federal Government needs to list new hepatitis C medicines on the PBS without further delay, according to the peak body representing the interests of a quarter of a million …
PBAC moves to reassure on biosimilars
The PBAC has issued a statement intending to reassure the public about the safety of biosimilar copies of biologic drugs, in a bid to stamp out “misinformation” which could slow …
Medicines delisting: the PBAC principles
To guide its decisions on medicines delisting including those available OTC, the Department of Health has published principles set by the Pharmaceutical Benefits Advisory Committee. The delisting principles considered appropriate …
Prof Andrew Wilson to chair PBAC
Professor Andrew Wilson has been named as the new Chair of the Pharmaceutical Benefits Advisory Committee. “I congratulate Professor Wilson on his appointment and look forward to continuing to receive …
GMiA welcomes ‘a’ flagging of biosimilars
The Generic Medicines Industry Association has welcomed the PBAC’s decision to consider “a” flagging of biosimilars, and to list biosimilar insulin (Basaglar) on the PBS. Basaglar is the first biosimilar …
Cancer drug delays not due to PBAC processes
The Pharmaceutical Benefits Advisory Committee has spoken out against a perception that delays in access to the listing of cancer (and other) medicines are due to PBAC processes. PBAC informed …
Suzanne Hill to step down as PBAC chair
Industry leaders have congratulated Dr Suzanne Hill, the Chair of the Pharmaceutical Benefits Advisory Committee, who is set to take on a new role with the World Health Organization. Dr …